allosteric TKIs

Oncology

pharmaphorum podcast Episode 205a - Amy Burroughs, Terns Pharmaceuticals

Doing good in people’s lives: Amy Burroughs discusses CML

Amy Burroughs, CEO, Terns Pharmaceuticals, discusses available treatments for CML, the potential of allosteric TKIs, and the wider oncology landscape.

News

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks